Detalhe da pesquisa
1.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
2.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062004
3.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755235
4.
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial.
Haematologica
; 107(7): 1726-1730, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295081
5.
Exploring the impact of dexamethasone on gene regulation in myeloma cells.
Life Sci Alliance
; 6(9)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37524526
6.
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Leukemia
; 33(1): 159-170, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29967379
7.
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection.
Genome Med
; 8(1): 49, 2016 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27121964
8.
Initial treatment of transplant-eligible patients in multiple myeloma.
Expert Rev Hematol
; 7(1): 43-53, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24392968
9.
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biol. blood marrow transplant
; 21(12): [28 p.], diciembre, 2015.
Artigo
em Inglês
| URUCAN | ID: bcc-4990